New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American Thoracic Society (ATS) 2019 International Conference.
Novel START, an open-label trial designed to reflect real-world practice, assesses the effectiveness of Symbicort Turbuhaler as a potential anti-inflammatory reliever taken as-needed, compared with two of the most commonly used treatment regimens in mild asthma: as-needed short-acting beta2-agonist (SABA) alone or low-dose inhaled corticosteroid (ICS) maintenance treatment plus as-needed SABA.
AstraZeneca will also present new science supporting its biologics portfolio and pipeline. Presentations include: data from an integrated analysis of Fasenra’s (benralizumab) long-term efficacy and safety profile and ability to reduce oral corticosteroid use in patients with severe eosinophilic asthma; the impact of tezepelumab on hospitalisation and emergency department visits; and the first-in-human data for the company’s potential inhaled biologic AZD1402, an IL-4Ra antagonist, currently in development for the treatment of asthma.
Tom Keith-Roach, Senior Vice President, Respiratory, AstraZeneca, said: “We look forward to sharing the results from the Novel START trial which looks at Symbicort used as an anti-inflammatory reliever versus short-acting beta2-agonist, the most commonly used reliever therapy today.
“In biologics, new long-term efficacy and safety data continues to build Fasenra’s clinical profile, and with more than 70 abstracts overall, AstraZeneca is demonstrating its commitment to advancing respiratory science.”